Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
2017
Athyros, V. G., Papageorgiou A., Athyrou V., & Karagiannis A. (2017).  Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre. J Clin Lipidol. 11(1), 306-307.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2017).  Semaglutide, lipid-lowering drugs, and NAFLD.. Lancet Diabetes Endocrinol. 5(5), 329-330.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.. Metabolism. 71, 17-32.
2016
Stavropoulos, K., Imprialos K. P., Boutari C., Athyros V. G., & Karagiannis A. I. (2016).  Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. J Clin Hypertens (Greenwich). 18(10), 1073.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., Athyros V. G., & Karagiannis A. I. (2016).  Current challenges in antihypertensive treatment in the elderly.. Pol Arch Med Wewn. 126(7-8), 540-51.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2016).  Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs.. Curr Vasc Pharmacol. 14(2), 208-10.
Katsiki, N., Athyros V. G., & Karagiannis A. (2016).  Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.. Curr Vasc Pharmacol. 14(6), 523-533.
Athyros, V. G., & Mikhailidis D. P. (2016).  High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice.. J Diabetes Complications. 30(1), 9-11.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Katsiki, N., Kollari E., Dardas S., Dardas P., Haidich A-B., Athyros V. G., et al. (2016).  Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study.. Open Cardiovasc Med J. 10, 64-8.
2015
Athyros, V. G., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., & Mikhailidis D. P. (2015).  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World J Gastroenterol. 21(22), 6820-34.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2015).  Cardiovascular Risk in Middle East Populations: A Call to Action.. Angiology. 66(9), 801-2.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2015).  Contrast-Induced Nephropathy: An "All or None" Phenomenon?. Angiology. 66(6), 508-13.
Athyros, V. G., Katsiki N., Karagiannis A., & Radak D. (2015).  Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy.. Curr Vasc Pharmacol. 13(2), 223-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2015).  Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease.. Curr Vasc Pharmacol. 13(3), 366-7.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.. Curr Vasc Pharmacol. 13(6), 696-8.
Preiss, D., Campbell R. T., Murray H. M., Ford I., Packard C. J., Sattar N., et al. (2015).  The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.. Eur Heart J. 36(24), 1536-46.
Daskalopoulos, G., Karkanaki A., Piouka A., Prapas N., Panidis D., Gkeleris P., et al. (2015).  Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.. Curr Vasc Pharmacol. 13(6), 788-800.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2015).  Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors.. Curr Med Res Opin. 31(3), 435-8.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus.. J Diabetes Complications. 29(1), 142-5.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές